Meyka Pro banner
StemRIM

StemRIM Fundamental Analysis (JPX: 4599.T)

4599.TJPX
HealthcareBiotechnology
¥351.00
¥3.00(0.85%)
Japanese Market opens in 10h 48m

StemRIM Fundamental Analysis (JPX: 4599.T)

StemRIM (JPX: 4599.T) shows weak financial fundamentals with a PE ratio of -11.78, profit margin of 0.00%, and ROE of -27.86%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position25.79%
PEG Ratio-1.94
Current Ratio52.97

Areas of Concern

ROE-27.86%
Operating Margin0.00%
We analyze 4599.T's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 2.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
2.7/100

We analyze 4599.T's fundamental strength across five key dimensions:

Efficiency Score

Weak

4599.T struggles to generate sufficient returns from assets.

ROA > 10%
-29.39%

Valuation Score

Excellent

4599.T trades at attractive valuation levels.

PE < 25
-11.78
PEG Ratio < 2
-1.94

Growth Score

Weak

4599.T faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

4599.T maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
52.97

Profitability Score

Weak

4599.T struggles to sustain strong margins.

ROE > 15%
-2785.77%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is 4599.T Expensive or Cheap?

P/E Ratio

4599.T trades at -11.78 times earnings. This suggests potential undervaluation.

-11.78

PEG Ratio

When adjusting for growth, 4599.T's PEG of -1.94 indicates potential undervaluation.

-1.94

Price to Book

The market values StemRIM at 3.61 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.61

EV/EBITDA

Enterprise value stands at -14.65 times EBITDA. This is generally considered low.

-14.65

How Well Does 4599.T Make Money?

Net Profit Margin

For every $100 in sales, StemRIM keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-27.86 in profit for every $100 of shareholder equity.

-27.86%

ROA

StemRIM generates $-29.39 in profit for every $100 in assets, demonstrating efficient asset deployment.

-29.39%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

4599.T converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-11.78

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-1.94

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.61

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

52.97

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.28

vs 25 benchmark

ROA

Return on assets percentage

-0.29

vs 25 benchmark

ROCE

Return on capital employed

-0.31

vs 25 benchmark

How 4599.T Stacks Against Its Sector Peers

Metric4599.T ValueSector AveragePerformance
P/E Ratio-11.7832.14 Better (Cheaper)
ROE-27.86%550.00% Weak
Net Margin0.00%30133.00% Weak
Debt/Equity0.000.56 Strong (Low Leverage)
Current Ratio52.975.70 Strong Liquidity
ROA-29.39%3.00% Weak

4599.T outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews StemRIM's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ